Our data revealed for the first time that the expression levels of FTX were elevated in RB and sharpen the malignant phenotypes of RB both in vitro and in vivo by modulating miR-320a and WNK1, suggesting that FTX might be a novel therapeutic target in this disease. The gene discussed is WNK1; the disease is retinoblastoma.